Neutrophils and B Cells Express XCR1 Receptor and Chemotactically Respond to Lymphotactin

Huang, Hui; Li, Fang; Cairns, Chantelle M.; Gordon, John; Xiang, Jim

doi:10.1006/bbrc.2001.4363

Cited by 56 publications

(39 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By a nonquantitative PCR assay, our data confirmed previous experiments (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) and showed that the constitutive and activation-induced XCL1 message detected in PBMC was also present in both CD4 ϩ and CD8 ϩ lymphocytes. However, comparison of data obtained by conventional PCR (Fig.…”

Section: Discussionsupporting

confidence: 90%

“…Two major problems still need to be solved. Firstly, although the expression of XCL1 has been described virtually in all lymphocyte populations, including CD8 ϩ lymphocytes (7)(8)(9)(10)(11)(12), CD4 ϩ lymphocytes (19 -21), NK cells (7,13,14), and ␥␦ ϩ T cells (17,18) under a variety of experimental conditions, the available data are mostly based on nonquantitative PCR analyses, and no thorough comparison of the actual XCL1 synthesis and/or the expression in different T cell populations was attempted. Secondly, although clear XCL1 effects other than lymphocyte migration were described on several cell types, including CD4 ϩ T cells (22,57), this issue is as yet incompletely addressed, and the position of XCL1 within the cytokine/ chemokine network is still elusive.…”

Section: Discussionmentioning

confidence: 99%

“…Until a few years ago, the only known role for the ␦-chemokine fractalkin and the ␥-chemokine lymphotactin (XCL1) 3 was the ability to promote migration of different leukocyte subpopulations. In particular, XCL1 is efficiently chemotactic for activated CD4 ϩ and CD8 ϩ T cells and NK cells (7)(8)(9); more recently, a chemotactic activity on neutrophils and B cells was also demonstrated (10).…”

mentioning

confidence: 99%

See 2 more Smart Citations

CD8+αβ+ T Cells That Lack Surface CD5 Antigen Expression Are a Major Lymphotactin (XCL1) Source in Peripheral Blood Lymphocytes

Stievano

Tosello

Marcato

et al. 2003

The Journal of Immunology

View full text Add to dashboard Cite

To better characterize the cellular source of lymphotactin (XCL1), we compared XCL1 expression in different lymphocyte subsets by real-time PCR. XCL1 was constitutively expressed in both PBMC and CD4+ cells, but its expression was almost 2 log higher in CD8+ cells. In vitro activation was associated with a substantial increase in XCL1 expression in both PBMC and CD8+ cells, but not in CD4+ lymphocytes. The preferential expression of XCL1 in CD8+ cells was confirmed by measuring XCL1 production in culture supernatants, and a good correlation was found between figures obtained by real-time PCR and XCL1 contents. XCL1 expression was mostly confined to a CD3+CD8+ subset not expressing CD5, where XCL1 expression equaled that shown by γδ+ T cells. Compared with the CD5+ counterpart, CD3+CD8+CD5− cells, which did not express CD5 following in vitro activation, showed preferential expression of the αα form of CD8 and a lower expression of molecules associated with a noncommitted/naive phenotype, such as CD62L. CD3+CD8+CD5− cells also expressed higher levels of the XCL1 receptor; in addition, although not differing from CD3+CD8+CD5+ cells in terms of the expression of most α- and β-chemokines, they showed higher expression of CCL3/macrophage inflammatory protein-1α. These data show that TCR αβ-expressing lymphocytes that lack CD5 expression are a major XCL1 source, and that the contribution to its synthesis by different TCR αβ-expressing T cell subsets, namely CD4+ lymphocytes, is negligible. In addition, they point to the CD3+CD8+CD5− population as a particular T cell subset within the CD8+ compartment, whose functional properties deserve further attention.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

CD8+αβ+ T Cells That Lack Surface CD5 Antigen Expression Are a Major Lymphotactin (XCL1) Source in Peripheral Blood Lymphocytes

Stievano

Tosello

Marcato

et al. 2003

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Naïve splenic T lymphocytes were nylon wool purified from BALB/ c mice as previously described 18 (>99% purity as determined using the anti -CD3 antibody by flow cytometry, data not shown). T cells were activated in DMEM, 10% FCS, IL -2 ( 20 U /mL ), and Con A (2 g/mL ) for 4 days.…”

Section: Rt -Pcr Analysismentioning

confidence: 99%

“…18 Recombinant IP-10 ( R&D Systems, Minneapolis, MN ), diluted in DMEM/ 0.1% bovine serum albumin ( BSA ) to 0.1 -1000 ng/ mL, was added to triplicate lower chambers of the wells, and 10 5 activated T lymphocytes in DMEM/ BSA were added to the upper chambers. After incubation for 2 hours at 378C, the cells that had not migrated into the membranes were wiped from the upper surfaces of the membranes, which were then fixed in 70% methanol and stained using a Diff-Quik kit ( American Scientific Products, McGraw Hill, IL ).…”

Section: Chemotaxis Assaymentioning

confidence: 99%

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors

et al. 2002

Self Cite

View full text Add to dashboard Cite

We have constructed two recombinant adenoviral vectors AdVIP -10 and AdVIL -18 expressing the functional chemokine IFNinducible protein ( IP ) -10 and cytokine interleukin ( IL ) -18, respectively. Injection of either AdVIP -10 or AdVIL -18 subcutaneously into tumor nodules derived from the J558 murine myeloma cell line delayed some tumor growth but it was not curative in all cases. Coinjection of these two vectors at the same tumor nodule not only significantly suppressed the tumor growth, but also cured established tumors in 8 of 10 ( 80% tumor free ) mice. The latter treatment stimulated T -cell infiltration into tumors in association with tumor necrosis formation, induced a type 1 immune response and induced the activation of J558 tumor -specific cytotoxic T lymphocytes. Moreover, the antitumor activity of IP -10 and IL -18 combined gene therapy was significantly diminished in mice with depletion of either CD4 + ( 50% tumor free ) or CD8 + ( 40% tumor free ) T cells, and completely lost ( 0% tumor free ) in T celldeficient nude and IFN -knockout mice, indicating the critical roles of T cells and IFN -in this therapeutical model. Taken together, the findings of this study demonstrate that the combined use of two adenoviral vectors expressing IP -10 and IL -18, respectively, synergize to facilitate regression of established tumors. These observations also suggest the potential use of doublerecombinant adenoviral vectors expressing chemokines and immunomodulatory cytokines in cancer gene therapy.

show abstract

Expression of activation‐induced, T cell–derived, and chemokine‐related cytokine/lymphotactin and its functional role in rheumatoid arthritis

Blaschke¹,

Middel²,

Dorner³

et al. 2003

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

Neutrophils and B Cells Express XCR1 Receptor and Chemotactically Respond to Lymphotactin

Cited by 56 publications

References 25 publications

CD8+αβ+ T Cells That Lack Surface CD5 Antigen Expression Are a Major Lymphotactin (XCL1) Source in Peripheral Blood Lymphocytes

CD8+αβ+ T Cells That Lack Surface CD5 Antigen Expression Are a Major Lymphotactin (XCL1) Source in Peripheral Blood Lymphocytes

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors

Expression of activation‐induced, T cell–derived, and chemokine‐related cytokine/lymphotactin and its functional role in rheumatoid arthritis

Contact Info

Product

Resources

About